Antibacterial Resistance Leadership Group 2.0: Back to Business

Abstract In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0. The Antibacterial Resistance Leadership Group (ARLG) was recently competitively renewed by the National Institutes of Allergy and Infectious Diseases to prioritize, design, implement, and conduct clinical studies to address antibacterial resistance. This article summarizes scientific progress in the original funding period and outlines the scientific agenda and programmatic priorities of ARLG 2.0 in its second funding cycle.